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Clinical PerspectiveWhat Is New?In a large community‐based cohort, for the first time, we described the distribution of circulating neprilysin in the general community.We observed that neprilysin does not correlate with natriuretic peptide levels.Low soluble neprilysin was paradoxically associated with an adverse cardiometabolic and smoking profile.What Are the Clinical ImplicationsContrary to the previously proposed inverse relationship between neprilysin and natriuretic peptides in humans, we observed no such interaction in a large community‐based cohort.Our findings emphasize the complexity of the human neprilysin--natriuretic peptide system and suggest that low soluble neprilysin levels may be related to diastolic dysfunction and an adverse cardiometabolic profile.

Introduction {#jah34279-sec-0008}
============

Since the publication of the landmark PARADIGM‐HF (Prospective Comparison of ARNI \[Angiotensin Receptor‐Neprilysin Inhibitor\] with ACEI \[Angiotensin‐Converting‐Enzyme Inhibitor\] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial demonstrating a reduction in mortality and heart failure (HF) hospitalization with neprilysin inhibition in HF with reduced ejection fraction (HFrEF),[1](#jah34279-bib-0001){ref-type="ref"} there has been renewed interest in the neprilysin pathway in HF. Neprilysin is a membrane‐bound and soluble metalloprotease that most notably breaks down brain natriuretic peptide (BNP), but it is rather nonspecific in substrate selectivity and breaks down both beneficial substances (A‐type natriuretic peptide \[ANP\], C‐type natriuretic peptide \[CNP\], adrenomedullin, bradykinin) and potentially deleterious substances (endothelin, angiotensin I, angiotensin II, substance P, antidiuretic hormone, oxytocin, IL1B \[interleukin 1β\], chemotactic peptide).[2](#jah34279-bib-0002){ref-type="ref"}

Most research on neprilysin to date has focused on HFrEF,[3](#jah34279-bib-0003){ref-type="ref"} with very few data available on HF with preserved ejection fraction (HFpEF) and only 1 small study of 144 patients that showed no prognostic value for neprilysin as a biomarker in HFpEF.[4](#jah34279-bib-0004){ref-type="ref"} Importantly, no data are available on plasma neprilysin levels in community members who may be at risk for HFpEF. Consequently, we sought to better understand the clinical correlates of soluble circulating neprilysin as a biomarker and its relationship to diastolic dysfunction (DD) and incident HF in a cohort compiled from an age‐ and sex‐stratified random sample of the adult population of Olmsted County, Minnesota.[5](#jah34279-bib-0005){ref-type="ref"} We hypothesized (1) that interindividual variability in circulating neprilysin exists related to clinical factors and (2) that higher neprilysin levels would correlate with lower natriuretic peptide levels, worse DD, and subsequent clinical incident HFpEF.

Methods {#jah34279-sec-0009}
=======

Study Population {#jah34279-sec-0010}
----------------

The design of this community‐based cohort study has been described previously.[5](#jah34279-bib-0005){ref-type="ref"}, [6](#jah34279-bib-0006){ref-type="ref"}, [7](#jah34279-bib-0007){ref-type="ref"}, [8](#jah34279-bib-0008){ref-type="ref"} From 1997 to 2000, a sex‐ and age‐stratified random sample (n=2042) of Olmsted County residents aged ≥45 years underwent physical examination, echocardiogram, and phlebotomy for biorepository samples. The study was approved by the institutional review board, and all participants gave informed consent. The data, analytic methods, and study materials will not be made available to other researchers for the purpose of reproducing the results. Trained nurse chart abstractors recorded risk factors or prevalent cardiovascular disease. The current analysis included the 1536 (75%) participants with remaining biorepository samples. Using the resources of the Rochester Epidemiology Project,[9](#jah34279-bib-0009){ref-type="ref"} electronic linkage for HF incidence (outpatient or hospitalized diagnosis) and all‐cause mortality were performed separately. Participants not known to have the outcome of interest were censored at the last known clinical follow‐up at the time of each linkage.

Soluble Neprilysin Assay {#jah34279-sec-0011}
------------------------

Plasma neprilysin was measured in previously unthawed EDTA plasma samples using a commercially available sandwich ELISA assay for soluble neprilysin (details in Data [S1](#jah34279-sup-0001){ref-type="supplementary-material"} and Table [S1](#jah34279-sup-0001){ref-type="supplementary-material"}). The intra‐ and interassay variability was 7.5% and 9.5%, respectively. All measurements were taken in duplicate. A freeze--thaw analysis was performed on other control plasma samples and found that neprilysin levels were stable for up to 2 freeze--thaw cycles.

Natriuretic Peptide Assays {#jah34279-sec-0012}
--------------------------

Plasma ANP and BNP were determined by immunoradiometric assay using antibody to human ANP and BNP, as described previously.[8](#jah34279-bib-0008){ref-type="ref"}, [10](#jah34279-bib-0010){ref-type="ref"}, [11](#jah34279-bib-0011){ref-type="ref"} Plasma NT‐proANP (N‐terminal pro‐ANP) levels were determined by radioimmunoassay, and plasma NT‐proBNP levels were measured using the Elecsys NT‐proBNP electrochemiluminescence immunoassay (Roche Diagnostics). Plasma CNP was measured from with a competitive radioimmunoassay using an antibody that detects human CNP‐22.[12](#jah34279-bib-0012){ref-type="ref"}

Assessment of Ventricular Structure and Function {#jah34279-sec-0013}
------------------------------------------------

The echocardiographic methods have been described in detail[5](#jah34279-bib-0005){ref-type="ref"}, [6](#jah34279-bib-0006){ref-type="ref"} (details in Data [S1](#jah34279-sup-0001){ref-type="supplementary-material"}). As a sensitivity analysis, DD and its relationship to neprilysin were assessed after excluding the 35 (2%) community participants with low ejection fraction (\<45%).

Statistical Analysis {#jah34279-sec-0014}
--------------------

Continuous variables are reported as mean (standard deviation) or median (interquartile range \[IQR\]) depending on the data distribution as assessed by visual inspection of box plots. Categorical data are reported as number (percentage). For analyses utilizing neprilysin as a continuous variable, natural logarithm transformation was applied to approximate normality before analyses. Regression methods, linear or logistic, were used to test for trends in characteristics across neprilysin tertiles while controlling for age, sex, body mass index, and smoking history. Associations of neprilysin with outcomes were assessed using Cox proportional hazards regression with participants' event data censored at last known clinical follow‐up. In these analyses, neprilysin was analyzed as both a trend across the tertiles and with the lowest tertile as the referent group, and results are presented as hazard ratios and associated confidence intervals after adjustment for age, sex, body mass index (BMI; kg/m^2^), and smoking history. The proportional hazards assumption was evaluated both visually, by plotting residuals versus time, and formally, by testing for a correlation between residual and time. No violations of the proportional hazards assumption were noted. In supplemental analyses, correlation among neprilysin levels and characteristics were repeated within the group of clinically normal nonsmoking individuals. Also in supplemental analyses, in an attempt to look at the phenotype of participants with extreme neprilysin levels, we analyzed participants below the median versus \>100 times above the median and those with levels below the 5th percentile and above the 95th percentile. Similar analyses were conducted to compare participants across these extreme subgroups. To assess effect modification by smoking status, the association of clinical characteristics and neprilysin levels was evaluated within smoking subgroups. An interaction between smoking status and neprilysin was also evaluated as it related to clinical characteristics, and no strong interactions were noted (data not shown). All tests were 2‐sided, and *P*\<0.05 was considered significant. All analyses were performed using SAS v9.4 (SAS Institute).

Results {#jah34279-sec-0015}
=======

Study Population and Baseline Characteristics {#jah34279-sec-0016}
---------------------------------------------

The overall cohort (n=1536) represented a middle aged to elderly cohort with a median age of 62 years (IQR: 54--70 years), and 97% were white (Table [1](#jah34279-tbl-0001){ref-type="table"}; Table [S2](#jah34279-sup-0001){ref-type="supplementary-material"}). The population was generally overweight with a median BMI of 27.5 (IQR: 24.8--31.2). A third of patients (n=439, 29%) had hypertension, and 7% (n=114) had diabetes mellitus. Half the participants (n=774, 51%) were either active or prior smokers. Renal function was normal on average with a median creatinine level of 0.8 mg/dL (IQR: 0.7--1.0 mg/dL). In addition, 98% of the population had preserved ejection fraction, and 29% (n=402) of the overall population had DD with 8% (n=105) having moderate or severe DD. These values did not change appreciably after excluding the 35 participants with reduced ejection fraction (Table [S2](#jah34279-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline Characteristics of Study Population

                              n      Result
  --------------------------- ------ --------------------
  Age, y                      1536   61.6 (53.6--70.4)
  Female, n (%)               1536   803 (52)
  White race, n (%)           1536   1497 (97)
  BMI, kg/m^2^                1535   27.5 (24.8--31.2)
  BNP, pg/mL                  1535   15.0 (5.8--32.0)
  NT‐proBNP, pg/mL            1494   69.9 (28.6--142.3)
  ANP                         1473   11.8 (7.2--16.4)
  NT‐proANP                   1448   2236 (1428--3385)
  CNP                         1413   13.0 (10.0--16.4)
  Aldosterone                 1283   4.7 (2.5--8.0)
  GFR, mL/min per 1.73 m^2^   1492   82.4 (71.6--89.2)
  Adiponectin                 1529   9.7 (6.5--14.4)
  Neprilysin, ng/mL           1536   3.9 (1.0--43.0)

Data are shown as median (interquartile range) except as noted. ANP indicates A‐type natriuretic peptide; BMI, body mass index; BNP, brain (B‐type) natriuretic peptide; CNP, C‐type natriuretic peptide; GFR, glomerular filtration rate (Modification of Diet in Renal Disease); NT‐pro, N‐terminal pro.

Soluble Neprilysin Levels in the Community {#jah34279-sec-0017}
------------------------------------------

The distribution of soluble neprilysin levels was skewed with a median of 3.9 ng/mL (IQR: 1.0--43.0 ng/mL). There were no significant associations between soluble neprilysin levels and age by correlation (Figure [1](#jah34279-fig-0001){ref-type="fig"}) or for tertiles of soluble neprilysin with age, sex, or renal function (Tables [2](#jah34279-tbl-0002){ref-type="table"} and [3](#jah34279-tbl-0003){ref-type="table"}). Similarly, there were no significant relationships between BMI, adiponectin, or aldosterone and soluble neprilysin.

![Scatter plot of age (*x*‐axis) vs soluble neprilysin (sNEP; *y*‐axis log scale) by sex. The Spearman correlation coefficients between age and neprilysin were −0.04 overall, −0.04 for male participants, and −0.03 for female participants.](JAH3-8-e012943-g001){#jah34279-fig-0001}

###### 

Lack of Correlation of Neprilysin Levels With Age, BMI, Renal Function, Natriuretic Peptides, and Neurohormonal Activation

                                   Serum Neprilysin (Spearman correlation)   *P* Value
  -------------------------------- ----------------------------------------- -----------
  Age, per year (n=1536)           −0.04                                     0.16
  BMI, per kg/m^2^ (n=1535)        −0.04                                     0.16
  SBP (n=1532)                     −0.02                                     0.39
  DBP (n=1531)                     −0.04                                     0.16
  BNP, pg/mL (n=1535)              −0.001                                    0.96
  NT‐proBNP (n=1535)               −0.02                                     0.47
  ANP (n=1473)                     −0.03                                     0.22
  NT‐proANP (n=1448)               −0.02                                     0.42
  CNP (n=1413)                     0.01                                      0.67
  Aldosterone (n=1283)             0.004                                     0.89
  GFR, mL/min/1.73 m^2^ (n=1492)   −0.007                                    0.80
  Adiponectin (n=1529)             −0.03                                     0.24
  Ejection fraction (n=1536)       0.003                                     0.92
  E/A ratio (n=1489)               0.03                                      0.25
  E/e′ (n=1293)                    0.01                                      0.62
  Left atrial size (n=1492)        −0.01                                     0.75
  Estimated PASP (n=1083)          −0.05                                     0.11

ANP indicates A‐type natriuretic peptide; BMI, body mass index; BNP, brain (B‐type) natriuretic peptide; CNP, C‐type natriuretic peptide; DBP, diastolic blood pressure; GFR, glomerular filtration rate; NT‐pro, N‐terminal pro; PASP, pulmonary artery systolic pressure; SBP, systolic blood pressure.

###### 

Clinical Characteristics and Biomarkers by Neprilysin Tertiles

  Variable                                                      sNEP ≤1.4 (n=516)         sNEP 1.5--22.6 (n=514)    sNEP \>22.6 (n=506)       Unadjusted Trend *P* Value   BMI‐Adjusted Trend *P* Value   Adjusted Trend *P* Value[a](#jah34279-note-0005){ref-type="fn"}
  ------------------------------------------------------------- ------------------------- ------------------------- ------------------------- ---------------------------- ------------------------------ -----------------------------------------------------------------
  Clinical characteristics                                                                                                                                                                                
  Age at exam, y                                                63.52±10.35               62.16 ±10.41              62.79±10.83               0.27                         0.25                           0.16
  Female                                                        270 (52)                  275 (54)                  258 (51)                  0.67                         0.59                           0.11
  BMI, kg/m^2^                                                  28.30±5.30                28.76±5.54                27.99±5.05                0.37                         ...                            0.30
  BMI \>30, kg/m^2^                                             166 (32)                  186 (36)                  139 (27)                  0.11                         ...                            0.08
  Increased WC[b](#jah34279-note-0006){ref-type="fn"}           165 (32)                  183 (36)                  158 (31)                  0.79                         ...                            0.91
  Smoking status                                                                                                                              \<0.001                      \<0.001                        \<0.001
  Never                                                         217 (42)                  254 (50)                  286 (57)                                                                              
  Former                                                        234 (45)                  214 (42)                  192 (38)                                                                              
  Current                                                       64 (12)                   43 (8)                    27 (5)                                                                                
  Current/former smoker                                         298 (58)                  257 (50)                  219 (43)                  \<0.001                      \<0.001                        \<0.001
  Diabetes mellitus                                             41 (8)                    37 (7)                    36 (7)                    0.61                         0.73                           0.86
  Hypertension                                                  164 (32)                  144 (28)                  131 (26)                  0.04                         0.05                           0.09
  AF/flutter                                                    31 (6)                    25 (5)                    27 (5)                    0.63                         0.62                           0.82
  CAD                                                           60 (12)                   64 (12)                   58 (11)                   0.94                         0.96                           0.48
  Prior MI                                                      25 (5)                    23 (4)                    26 (5)                    0.83                         0.80                           0.50
  Prior stroke                                                  13 (3)                    4 (1)                     8 (2)                     0.24                         0.24                           0.34
  Metabolic syndrome                                            103 (20)                  127 (25)                  97 (19)                   0.77                         0.91                           0.71
  SDP, mm Hg                                                    134.17±21.97              131.79±21.00              132.53±21.40              0.22                         0.28                           0.49
  DBP, mm Hg                                                    74.10±10.55               73.29±10.30               73.26±9.76                0.19                         0.24                           0.17
  Total cholesterol                                             204.79±33.22              202.23±34.61              203.32±36.98              0.50                         0.48                           0.66
  Antilipemic therapy                                           96 (20)                   88 (18)                   71 (15)                   0.03                         0.04                           0.07
  Creatinine                                                    0.80 (0.70--1.00)         0.80 (0.70--0.90)         0.80 (0.70--1.00)         0.28                         0.26                           0.31
  Estimated GFR mL/min[c](#jah34279-note-0007){ref-type="fn"}   85.01±24.79               85.38±24.38               82.85±21.65               0.25                         0.25                           0.17
  GFR \<60 mL/min                                               54 (10)                   57 (11)                   59 (12)                   0.54                         0.55                           0.45
  Insulin (μU/mL)                                               4.80 (3.50--7.50)         5.50 (3.80--8.40)         5.00 (3.40--7.40)         0.94                         0.68                           0.51
  Serum glucose                                                 95.00 (89.00--101.00)     94.00 (89.00--102.00)     93.00 (88.00--100.00)     0.21                         0.28                           0.52
  Cardiac structure and function                                                                                                                                                                          
  EF                                                            62.76±7.21                62.94±7.19                62.65±7.25                0.80                         0.80                           0.63
  EF \<45%                                                      14 (3)                    10 (2)                    11 (2)                    0.56                         0.56                           0.78
  MS DD                                                         42 (9)                    37 (8)                    26 (6)                    0.04                         0.04                           0.08
  Mild/MS DD                                                    151 (33)                  130 (28)                  121 (27)                  0.02                         0.02                           0.06
  MS DD except EF \<45%                                         38 (9)                    30 (7)                    24 (5)                    0.06                         0.05                           0.07
  Mild/MS DD except EF \<45%                                    141 (32)                  121 (27)                  115 (26)                  0.04                         0.04                           0.07
  LVH                                                           134 (35)                  128 (32)                  133 (35)                  0.28                         0.32                           0.52
  E/A ratio                                                     1.09±0.43                 1.12±0.44                 1.10±0.37                 0.90                         0.97                           0.40
  E/e′                                                          8.59±3.08                 8.75±3.05                 8.61±3.15                 0.93                         0.90                           0.60
  Left atrial size                                              3.94±0.67                 3.89±0.63                 3.93±0.72                 0.68                         0.93                           0.79
  Estimated PASP                                                23.03±5.20                22.60±5.11                22.52±5.09                0.18                         0.21                           0.39
  Serum biomarkers                                                                                                                                                                                        
  Aldosterone                                                   4.90 (2.50--7.90)         4.30 (2.50--7.80)         4.90 (2.70--8.30)         0.84                         0.79                           0.71
  NT‐proANP                                                     2284.0 (1469.0--3554.0)   2077.0 (1329.0--3122.0)   2375.0 (1436.0--3433.0)   0.53                         0.46                           0.77
  NT‐proBNP                                                     75.36 (31.84--153.80)     62.30 (24.59--133.80)     68.52 (28.60--141.70)     0.61                         0.56                           0.88
  BNP                                                           15.70 (6.30--33.80)       13.70 (4.70--28.80)       15.85 (6.70--32.30)       0.85                         0.86                           0.57
  ANP                                                           11.60 (7.40--17.60)       12.05 (7.10--16.50)       11.65 (7.10--15.40)       0.19                         0.20                           0.31
  sNEP                                                          0.65 (0.40--0.96)         4.11 (2.13--8.80)         119.00 (43.68--576.20)    ...                          ...                            ...
  Adiponectin                                                   9.80 (6.60--15.40)        9.40 (6.40--14.30)        9.60 (6.40--14.05)        0.65                         0.47                           0.77
  Outcomes[d](#jah34279-note-0008){ref-type="fn"}                                                                                                                                                         
  Death, K--M (no. of events)                                                                                                                 0.007                        0.008                          0.24
  1 y                                                           0.99 (3)                  1.00 (2)                  0.99 (3)                                                                              
  5 y                                                           0.94 (29)                 0.95 (27)                 0.95 (25)                                                                             
  10 y                                                          0.86 (69)                 0.88 (60)                 0.87 (64)                                                                             
  HF, K--M (no. of events)                                                                                                                    0.80                         0.85                           0.28
  1 y                                                           0.98 (12)                 0.98 (8)                  0.97 (13)                                                                             
  5 y                                                           0.93 (34)                 0.94 (27)                 0.92 (36)                                                                             
  10 y                                                          0.86 (62)                 0.88 (52)                 0.87 (58)                                                                             

Data are shown as mean±SD, number (percentage), or median (interquartile range). AF indicates atrial fibrillation; ANP, A‐type natriuretic peptide; BMI, body mass index; BNP, brain (B‐type) natriuretic peptide; CAD, coronary artery disease; DD indicates diastolic dysfunction; EF, ejection fraction; GFR, glomerular filtration rate; HF, heart failure; K--M, Kaplan--Meier; LVH, left ventricular hypertrophy; MI, myocardial infarction; MS, moderate or severe; NT‐pro, N‐terminal pro; PASP, pulmonary artery systolic pressure; sNEP, serum neprilysin; WC, waist circumference.

Adjusted for age, sex, BMI, and smoking.

Increased WC defined by as \>102 cm in men, and \>88 cm in women.

By Modification of Diet in Renal Disease.

Outcome data presented showing K--M survival estimates and number of observed events at 1, 5, and 10 y.

Relationship Between Soluble Neprilysin and Natriuretic Peptides in the Community {#jah34279-sec-0018}
---------------------------------------------------------------------------------

The median BNP was 15 pg/mL (IQR: 6--32 pg/mL) and NT‐proBNP was 70 pg/mL (IQR: 29--142 pg/mL; Table [1](#jah34279-tbl-0001){ref-type="table"}). ANP and CNP were similarly within the normal range. Contrary to our original hypothesis, no evidence showed an inverse relationship between plasma neprilsyin and ANP, BNP, or CNP (Table [2](#jah34279-tbl-0002){ref-type="table"}). Even when considering the subset of community participants without known cardiovascular disease, smoking, or risk factors (to remove potential of residual confounding), similar results were observed (Table [S3](#jah34279-sup-0001){ref-type="supplementary-material"}).

Clinical and Neurohormonal Characteristics by Tertiles of Soluble Neprilysin Levels {#jah34279-sec-0019}
-----------------------------------------------------------------------------------

To better explore nonlinear interactions between high and low soluble neprilysin levels, the cohort was split into tertiles of neprilysin, creating low, intermediate, and high groups (Table [3](#jah34279-tbl-0003){ref-type="table"}). There was a paradoxical inverse association of neprilysin with echocardiographic DD (*P*=0.02) in which participants with the lowest neprilysin levels had greater prevalence of DD (33%) compared with the intermediate (28%) and high (27%) groups. This relationship was unchanged with exclusion of the 35 participants with low ejection fraction. There was also a greater prevalence of hypertension (*P*=0.04) and dysplipidemia therapy (*P*=0.03) in the lowest tertile neprilysin group (Figure [2](#jah34279-fig-0002){ref-type="fig"}). These associations remained after adjustment for BMI but were attenuated with additional adjustment for smoking status, age, and sex (Table [3](#jah34279-tbl-0003){ref-type="table"}). All natriuretic peptide, aldosterone, and adiponectin levels were similar across neprilysin tertiles, consistent with our observation of a lack of correlation described earlier.

![Median soluble neprilysin (sNEP) levels with interquartile ranges according to smoking status among participants. **A**, Overall. **B**, Those without any risk factors or cardiovascular disease (normal). **C**, Nonobese participants. **D**, Low ejection fraction (EF). **E**, Moderate/severe (MS) diastolic dysfunction (DD) with normal EF. **F**, Any DD with normal EF. MMS indicates mild/moderate/severe. *P* values are derived from the Wilcoxon rank sum test.](JAH3-8-e012943-g002){#jah34279-fig-0002}

Again, no evidence showed association between BMI and neprilysin levels before or after adjusting for age, sex, and smoking status. In fact, there was a paradoxical trend toward less obesity in patients in the highest tertile of neprilysin levels (*P*=0.08). In sensitivity analyses, extreme elevations in plasma neprilysin were also associated with lower BMI and less obesity (Tables [S4 and S5](#jah34279-sup-0001){ref-type="supplementary-material"}). The lack of a relationship of extreme elevation in neprilysin levels with BNP was also contradictory to a direct proteolytic effect of neprilysin on BNP, with paradoxically higher BNP levels in participants with extreme neprilysin elevation (Table [S5](#jah34279-sup-0001){ref-type="supplementary-material"}).

Relationship Between Smoking and Neprilysin Levels {#jah34279-sec-0020}
--------------------------------------------------

The strongest association of neprilysin levels was observed with prior or current smoking status (*P*\<0.001), with smoking prevalence highest in the low neprilysin tertile (58%), intermediate in the middle tertile (50%), and lowest in the highest tertile (43%; Table [3](#jah34279-tbl-0003){ref-type="table"}; Figure [3](#jah34279-fig-0003){ref-type="fig"}). Similarly, the group with extreme neprilysin elevation had the lowest rates of smoking (Tables [S4 and S5](#jah34279-sup-0001){ref-type="supplementary-material"}).

![Prevalence of smoking, hypertension, and diastolic dysfunction across low, intermediate (Int), and high neprilysin (NEP) tertiles. *P* values are trend tests for proportions across NEP tertiles.](JAH3-8-e012943-g003){#jah34279-fig-0003}

Plasma Neprilysin Levels as a Predictor of Incident Clinical HF and Death {#jah34279-sec-0021}
-------------------------------------------------------------------------

At 10 years there were 193 deaths and 172 incident HF events. The group with low soluble neprilysin had the highest mortality (*P*=0.009 compared with those in the highest tertile), even after adjustment for BMI (*P*=0.01) but not after adjustment for other comorbidities (*P*=0.18). Consistent with the relatively modest association of plasma neprilysin with DD, there was no apparent relationship between baseline neprilysin levels and development of incident clinical HF over a median of 10.7 years (IQR: 7.8--11.5 years; Table [3](#jah34279-tbl-0003){ref-type="table"}; Table [S2](#jah34279-sup-0001){ref-type="supplementary-material"}). The age‐, sex‐, BMI‐, and smoking‐adjusted hazard ratios for tertiles 2 and 3 of neprilysin compared with tertile 1 were 0.85 (95% CI, 0.64--1.01) and 0.85 (95% CI, 0.68--1.07) for mortality and 1.07 (95% CI, 0.76--1.51) and 1.21 (95% CI, 0.86--1.71) for HF.

Discussion {#jah34279-sec-0022}
==========

This study is the first to evaluate the distribution, clinical correlates, and outcomes of soluble circulating neprilysin levels in a well‐characterized, community‐based population. The major findings of our study are as follows: (1) smoking was strongly associated with lower soluble neprilysin levels; (2) low soluble neprilysin was paradoxically associated with worse DD, dyslipidemia, and hypertension; (3) soluble neprilysin levels did not independently predict subsequent HF hospitalization or death over a 10‐year period; and (4) contrary to the proposed proteolytic effect of soluble neprilysin on natriuretic peptides, we observed no relationship between soluble neprilysin and circulating ANP, BNP, or CNP in these community participants without HF. These data challenge our current understanding of the interaction and biological activity of circulating soluble neprilysin and natriuretic peptides in humans.

Role of Neprilysin Across the Spectrum of Asymptomatic Participants With Risk Factors for Clinical HF {#jah34279-sec-0023}
-----------------------------------------------------------------------------------------------------

Neprilysin is believed to be detrimental, given that inhibition in HFrEF demonstrated a marked reduction in mortality,[1](#jah34279-bib-0001){ref-type="ref"} and has been demonstrated in experimental studies to break down beneficial natriuretic peptides[13](#jah34279-bib-0013){ref-type="ref"}, [14](#jah34279-bib-0014){ref-type="ref"}, [15](#jah34279-bib-0015){ref-type="ref"}; however, neprilysin is a nonspecific peptidase with numerous substrates (both beneficial and harmful) potentially affected by its proteolytic action.[2](#jah34279-bib-0002){ref-type="ref"} Consequently, the proposed construct of neprilysin inhibiting natriuretic peptides as the primary clinically relevant pathway may be overly simplistic and may differ based on whether the study population has HFrEF or HFpEF or comprises asymptomatic patients at risk for DD, as in our study. In a prior small experiment in asymptomatic patients, neprilysin was shown to have an important role in inhibiting vasoconstriction, which may explain the association of lower neprilysin with hypertension and DD in our cohort.[13](#jah34279-bib-0013){ref-type="ref"}

Our study provides the first report of soluble neprilysin in a large‐scale, community‐based cohort, demonstrating both lack of association of natriuretic peptides with neprilysin and lack of independent prognostic value of neprilysin. These findings are similar to a recent report in which neprilysin did not demonstrate prognostic significance in HFpEF.[4](#jah34279-bib-0004){ref-type="ref"} The only randomized trial of neprilysin inhibition in HFpEF demonstrated a reduction in NT‐proBNP at 12 weeks that was not sustained through the duration of the trial at 36 weeks, suggesting a complex interaction between circulation natriuretic peptides and neprilysin.[16](#jah34279-bib-0016){ref-type="ref"} These data contrast with the established prognostic role of neprilysin in ambulatory HFrEF,[3](#jah34279-bib-0003){ref-type="ref"}, [17](#jah34279-bib-0017){ref-type="ref"} acute hospitalized HFrEF,[18](#jah34279-bib-0018){ref-type="ref"}, [19](#jah34279-bib-0019){ref-type="ref"} and the unequivocal beneficial impact of neprilysin inhibition in HFrEF.[1](#jah34279-bib-0001){ref-type="ref"} It is well established that extrapolating therapies from HFrEF to HFpEF have generally been unsuccessful,[20](#jah34279-bib-0020){ref-type="ref"} and further study of the role of soluble neprilysin in the development of HFpEF is required. In addition, it remains unclear whether tissue and soluble neprilysin have similar biological activity and tissue release in unselected participants.[2](#jah34279-bib-0002){ref-type="ref"} Our inability to demonstrate a correlation between active natriuretic peptides and soluble neprilysin questions this fundamental assumption and requires further investigation.

Prior Literature on Neprilysin--Natriuretic Peptide Interactions {#jah34279-sec-0024}
----------------------------------------------------------------

The natriuretic peptides are processed by both natriuretic peptide C receptor and by neprilysin; in patients without marked elevations in natriuretic peptides, neprilysin has been proposed to play a lesser role in natriuretic peptide breakdown.[21](#jah34279-bib-0021){ref-type="ref"}, [22](#jah34279-bib-0022){ref-type="ref"} This description may partially explain the lack of interaction between neprilysin and natriuretic peptides in our participants, who did not have HF or marked elevation in natriuretic peptides at baseline. However, in sensitivity analyses of extreme neprilysin elevation, these patients paradoxically had higher and not lower BNP levels; again, this result refutes the existing simplistic paradigm of neprilysin breaking down natriuretic peptides in HFpEF. Although it has been proposed that higher levels of BNP (\>916 pg/mL) can inhibit neprilysin activity, the levels of BNP in our cohort (even among those in the highest percentiles) were much lower and unlikely to cause such an effect in this range.[23](#jah34279-bib-0023){ref-type="ref"} Therefore, the mechanism for concordant elevation of soluble neprilysin and BNP in those with more prominent neprilysin levels is unclear and does not support the negative feedback hypothesis of elevated natriuretic peptides suppressing soluble neprilysin levels. Furthermore, the same study[23](#jah34279-bib-0023){ref-type="ref"} demonstrated that patients without HF had lower soluble neprilysin levels but paradoxically higher neprilysin activity than HF patients. In addition, correlation was poor between soluble neprilysin levels and biological activity, and this uncoupling may in part explain the lack of association between soluble neprilysin with natriuretic peptides in our study.

This existing paradigm of neprilysin--natriuretic peptide interactions derives from small acute studies of neprilysin inhibition[13](#jah34279-bib-0013){ref-type="ref"}, [14](#jah34279-bib-0014){ref-type="ref"}, [15](#jah34279-bib-0015){ref-type="ref"} or from populations with HFrEF, in which natriuretic peptides are in general elevated beyond the normal reference range and contribute to the pathophysiology of the HFrEF syndrome.[24](#jah34279-bib-0024){ref-type="ref"} In contrast, the centrality of BNP elevation in HFpEF and DD is not universal,[25](#jah34279-bib-0025){ref-type="ref"}, [26](#jah34279-bib-0026){ref-type="ref"} and BNP levels can be low in many patients with HFpEF and DD because of lower wall stress compared with HFrEF,[27](#jah34279-bib-0027){ref-type="ref"} particularly HFpEF of the obese[28](#jah34279-bib-0028){ref-type="ref"} and those with euvolemic exertional dyspnea.[29](#jah34279-bib-0029){ref-type="ref"}, [30](#jah34279-bib-0030){ref-type="ref"} Therefore, the large subset of HFpEF patients in whom natriuretic peptides are not elevated may not have an important neprilysin dependence with regard to their HF; this is supported by the results of our study in patients at risk for HFpEF and by a prior investigation in a small cohort with clinical HFpEF.[4](#jah34279-bib-0004){ref-type="ref"}

Soluble Neprilysin, Smoking, and DD {#jah34279-sec-0025}
-----------------------------------

One of the novel interactions observed in this study was the relationship between smoking and soluble neprilysin. Neprilysin is highly expressed in airways, pulmonary interstitium, and alveolar cells,[31](#jah34279-bib-0031){ref-type="ref"}, [32](#jah34279-bib-0032){ref-type="ref"}, [33](#jah34279-bib-0033){ref-type="ref"} which are susceptible to cigarette smoke--related epithelial injury and cellular loss. The observation of smoking being linked with low neprilysin levels is consistent with prior human lung tissue studies[34](#jah34279-bib-0034){ref-type="ref"} but, for the first time, was demonstrated in a general population--based cohort using circulating neprilysin levels. Smoking is a known risk factor for HFpEF[35](#jah34279-bib-0035){ref-type="ref"}, [36](#jah34279-bib-0036){ref-type="ref"}, [37](#jah34279-bib-0037){ref-type="ref"}, [38](#jah34279-bib-0038){ref-type="ref"} and is frequently associated with worse outcomes, DD,[39](#jah34279-bib-0039){ref-type="ref"} alveolar capillary remodeling, and pulmonary vascular disease in HFpEF,[40](#jah34279-bib-0040){ref-type="ref"}, [41](#jah34279-bib-0041){ref-type="ref"}, [42](#jah34279-bib-0042){ref-type="ref"} but the underlying pathophysiology driving these changes is unknown. Systemic inflammation linked to coronary microvascular and endothelial dysfunction has been proposed,[43](#jah34279-bib-0043){ref-type="ref"} but our study suggests another potential mechanism mediated by low neprilysin.

The association of low neprilysin levels with DD and hypertension suggests that there may be an increase in transforming growth factor β,[44](#jah34279-bib-0044){ref-type="ref"} endothelin, angiotensin, or other detrimental systemic mediators that may drive adverse left ventricular, aortic, pulmonary vascular,[45](#jah34279-bib-0045){ref-type="ref"} and alveolar capillary remodeling. In addition, absence of lung tissue neprilysin has been associated with exaggerated inflammation mediated by lack of clearance of tachykinins such as substance P.[31](#jah34279-bib-0031){ref-type="ref"}, [46](#jah34279-bib-0046){ref-type="ref"} Any or all of these mediators may underlie higher DD with low neprilysin, but we did not measure these substances in our study and this requires additional investigation. Smokers may also have reduced plasma neprilysin due to epigenetic mechanisms that affect *MME* (membrane metalloendopeptidase; the gene that encodes neprilysin) gene transcription and increased urinary neprilysin excretion.[34](#jah34279-bib-0034){ref-type="ref"}, [47](#jah34279-bib-0047){ref-type="ref"}

Limitations {#jah34279-sec-0026}
-----------

As with all transmembrane proteins, it is possible that circulating levels may not perfectly correlate with biologically active tissue levels, but this remains a limitation of all serological biomarker research. However, prior investigations have demonstrated low expression of neprilysin in lung tissue (at both protein and transcript levels) in smokers,[34](#jah34279-bib-0034){ref-type="ref"} which is concordant with our independent finding of low circulating neprilysin levels in smokers. This finding supports the validity of measured soluble neprilysin as a representation of tissue neprilysin levels. We previously demonstrated a linear correlation between neprilysin tissue expression and activity[48](#jah34279-bib-0048){ref-type="ref"}, that is lower the tissue expression less is the enzymatic activity. Prior investigations have also confirmed that circulating neprilysin indeed retains biologically active catalytic activity,[49](#jah34279-bib-0049){ref-type="ref"}, [50](#jah34279-bib-0050){ref-type="ref"} but this has not been consistently observed. We did not measure neprilysin activity in this study, and further investigation of the relationship between soluble neprilysin levels with serum and tissue activity is required. Serum BNP assays as currently measured have cross‐reactivity between the precursor proBNP, inactive BNP subtypes, and biologically active BNP1‐32 subtypes.[51](#jah34279-bib-0051){ref-type="ref"}, [52](#jah34279-bib-0052){ref-type="ref"} Consequently, it has been proposed that current serological assays for BNP may not detect bioactive BNP1‐32 reliably.[53](#jah34279-bib-0053){ref-type="ref"} This may have affected our observed lack of interaction between neprilysin and serologically measured BNP. However, in subgroup analyses, we observed a significant but paradoxical higher BNP level in patients with extreme elevations of neprilysin, and levels of NT‐proBNP, ANP, CNP, and NT‐ANP similarly showed no interaction with neprilysin. These results suggest that our observation of the lack of an inverse association between BNP and soluble neprilysin is real and deserves further investigation. The event rate for clinical HF was low in this study over 10 years of follow‐up, emphasizing the long duration of follow‐up needed to transition from risk factors to DD to clinical HFpEF. It is possible that despite the observed associations between low neprilysin levels and DD, our study was underpowered to detect true associations between low neprilysin, incident HFpEF, and mortality. These associations require further study in large combined population data sets.

Conclusions {#jah34279-sec-0027}
===========

Contrary to the previously proposed inverse relationship between neprilysin and natriuretic peptides in humans, we observed no such interaction in a large community‐based cohort. Nevertheless, our findings emphasize the complexity of the human neprilysin--natriuretic peptide system and suggest that low soluble neprilysin levels may be modestly related to DD and an adverse cardiometabolic profile. Further study of the relationship among smoking, soluble and tissue neprilysin activity, and DD may help us better understand how smoking contributes to DD. Whether it relates to less neprilysin‐related proteolysis of harmful substances such as angiotensin and endothelin requires further study.
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**Figure S1.** Inter and intra‐assay variability for neprilysin analysis demonstrating good correlation.
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